G laucoma is the leading cause of irreversible blindness globally. The most common forms of glaucoma are primary open-angle glaucoma (POAG) and primary angleclosure glaucoma (PACG) . For the population older than 40 years, the worldwide age-standardized prevalence of glaucoma is 3.54%; for POAG and PACG, it is 3.05% and 0.50%, respectively. 1 It is estimated there were 60.5 million patients with POAG and PACG worldwide in 2010, and that number will be 112 million by 2040. 1, 2 Elevated intraocular pressure (IOP)
is the major modifiable risk factor for POAG. Progression of POAG is arrested or reduced if the IOP is lowered by 30% to 50% from baseline levels. 3 Genetic factors play an important role in glaucoma. [4] [5] [6] Having a first-degree relative with glaucoma raises the likelihood of developing glaucoma by 9.4-fold relative to the general population. 7 A recent large-scale study estimated the heritability of glaucoma to be 70% using reconstructed family data. 8 The myocilin gene (MYOC) at the GLC1A locus was the first gene discovered to be associated with POAG. 9, 10 Pathogenic variants in MYOC have been found in 2% to 4% of individuals with POAG. 11, 12 The exact pathogenic mechanisms by which diseasecausing variants in MYOC might cause glaucoma have not been elucidated completely, but evidence supports a dominantnegative mechanism.
13,14
The p.Gln368Ter variant (rs74315329) is the most common MYOC variant among populations of European ancestry. 11, 12, 15 The association between p.Gln368Ter and POAG has an odds ratio (OR) greater than 10, with the p.Gln368Ter variant associated with younger age at onset and greater severity of IOP elevation. 16, 17 The estimated penetrance of p.Gln368Ter in glaucoma and ocular hypertension (OHT) has been inconsistent between family studies and general population-based studies. 11, 12, 15, [18] [19] [20] There are several potential explanations for this inconsistency. Estimates from family studies may be inflated because of ascertainment bias, aggregation of other genetic factors, and/or confounds by common environmental risk factors. Conversely, estimates from general population-based designs are likely to be low because of undersampling of cases (especially more severely affected cases) among volunteer-based studies. 20 Additionally, for both family studies and general population-based studies, statistical power is typically low because of the relatively low numbers of p.Gln368Ter carriers.
In this study, we explore the penetrance and association of MYOC p.Gln368Ter variant with glaucoma and OHT in white European individuals enrolled in the UK Biobank (UKBB) study and compare the results with registry-based studies.
Methods
The UKBB project is a large-scale prospective cohort study of approximately 500 000 individuals across the United Kingdom, aged between 40 and 69 years at the time of recruitment (2006) (2007) (2008) (2009) (2010) . Detailed information on the UKBB study is available online (http://www.ukbiobank.ac.uk/ resources/), and the genotype curation process is described in Bycroft et al. 21 The study was approved by the National Research Ethics Service Committee North West-Haydock, in accordance with the Declaration of Helsinki. Approval was also obtained from QIMR Berghofer Institute of Medical Research, the Southern Adelaide Clinical Human Research Ethics Committee of Flinders University, the University of Tasmania, and the Royal Victorian Eye and Ear Hospital, also in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
In the UKBB study, the genotypic data were imputed with IMPUTE4 (Oxford University Innovation), using the Haplotype Reference Consortium, UK10K, and 1000 Genomes Phase 3 reference panels. Among 487 409 participants passing genotyping quality control, 409 694 had white British ancestry based on self-reported race/ethnicity data. We identified 438 870 individuals who fell within the same genetic principal components-based clustering as those who self-reported white British ancestry, based on the first 2 genetic principal components (eFigure 1 in the Supplement).
Our previous study showed that the p.Gln368Ter variant can be imputed with high accuracy from genotyping arrays. 17 In this study, the imputation posterior probability for each of the 3 genotypes (GG [homozygous for the non-risk allele], AG, and AA [homozygous for the risk allele]) was used to identify p.Gln368Ter carriers. We calculated the genotype dosages based on imputation posterior probability. Because the dosage only ranged from 0 to 1.1, there were no p.Gln368Ter homozygous carriers in our study. For downstream analyses requiring best-guess genotypes, we set the dosage threshold of heterozygous AG at 0.8.
A subset of 112 690 UKBB participants underwent IOP measurements at the UKBB Assessment Centre using Reichert Ocular Response Analyzer (Reichert Technologies) 22 ; the detailed procedure is available online. 23 The mean cornealcompensated IOP (IOPcc; UKBB data field 5254 and 5262) and mean Goldmann-correlated IOP (IOPg; UKBB data fields 5255 and 5263) for each participant was calculated at the initial assessment visit, with measurements less than 5 mm Hg or greater than 60 mm Hg set as missing. Ocular hypertension or high IOP was defined as mean IOPcc of more than 21 mm Hg (n = 6827 of 84 481 [8.1%] ).
Among the 438 870 participants with genetic data, we removed participants who withdrew consent (n = 10 [<0.01%]). From the remaining 438 860 participants, individuals with glaucoma were identified via the following criteria: they (1) had an International Classification of Diseases, Ninth Revision (ICD-9) or Tenth Revision (ICD-10) diagnosis of primary openangle glaucoma, other glaucoma, or glaucoma, unspecified; (2) reported glaucoma in a survey item inquiring about eye problems or disorders (UKBB data field 6148); or (3) reported glaucoma in a survey item on self-reported noncancer illness (UKBB data field 20002). Individuals with POAG were identified by an ICD-9 or ICD-10 diagnosis of POAG. Among participants with IOP measurements, those with IOPcc measurements greater than 21 mm Hg were defined as having OHT or glaucoma, as were those individuals identified as having glaucoma. The information for age at glaucoma onset was gathered from UKBB data fields 4689 and 20009; field 21022 was regarded as age at recruitment.
Finally, individuals were selected as healthy control participants for glaucoma, POAG, and OHT if they (1) did not have other serious eye diseases (UKBB data field 6148; 26 576 individuals excluded) and (2) did not have other kinds of glaucoma diagnosed by ICD-9 or ICD-10 (diagnosed as a glaucoma suspect or diagnosed with PACG or secondary glaucoma; 947 individuals excluded). For control participants without POAG, 6886 individuals with other types of glaucoma were regarded as having not-available status. In total, 411 337 UKBB participants were included in this study. The flowchart illustrating selection criteria is shown in eFigure 2 in the Supplement.
In addition to examining population-based data, we considered participants from 2 registry-based studies: the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) and the Glaucoma Inheritance Study in Tasmania (GIST). Recruitment has been previously described. 24, 25 In brief, patients with glaucoma from Australia and New Zealand had been referred to the ANZRAG by their ophthalmologists. Participants in the GIST were recruited from surveys distributed to ophthalmology clinics and advertisements around Tasmania. Clinical information was collected by the patient's treating ophthalmologist. Participants from ANZRAG and GIST were considered to have glaucoma if they had glaucomatous visual field defects on standard automated perimetry and neuroretinal rim thinning (cup-to-disc ratio [CDR] ≥0.7 or CDR asymmetry ≥0.2). Individuals considered to be glaucoma suspects had OHT defined by an IOP greater than 21 mm Hg or had preperimetric glaucoma based on glaucomatous appearance of the optic disc or thinning or the retinal nerve fiber layer with no glaucomatous field changes. There were 2 arms to the ANZRAG and GIST component. First, there was a sequencing-based study within the ANZRAG and GIST data sets alone, to estimate the penetrance of p.Gln368Ter variants. Second, an array-based genome-wide association study allowed the estimation of the odds of glaucoma in a large sample of individuals with cases and control participants sourced from outside ANZRAG and GIST.
In the sequencing-based study, all participants with glaucoma and their relatives in the ANZRAG and GIST registries underwent Sanger sequencing for MYOC exon 3, as previously described. 26 Participants who were found to be MYOC p.Gln368Ter carriers were considered Sanger validated, and age at diagnosis was ascertained.
In the array-based study, we selected a total of 3071 unrelated participants with glaucoma from the ANZRAG and GIST registries and 6750 unscreened control participants from the Brisbane Adolescent Twin Study, the Australian Cancer Study, a study of inflammatory bowel diseases, and a study of endometriosis.
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Statistical Analysis
Descriptive statistics are presented as means (SDs) for continuous variables or as numbers (percentages) for categorical variables. Continuous variables were compared between groups using analysis of variance, whereas Pearson χ 2 or Fisher exact tests were used for categorical variables. We explored the prevalence of glaucoma and OHT in 4 age groups (younger than 50 years, 50-59 years, 60-65 years, and older than 65 years) of MYOC p.Gln368Ter carriers. We also investigated the cumulative risk of glaucoma by age 50 years, 60 years, and 65 years using a Cox model (adjusted for sex and the first 6 genetic principal components of the UKBB) or the KaplanMeier method (ANZRAG and GIST). The association between p.Gln368Ter dosage and disease status was estimated using logistic regression adjusted for sex, age, and the first 6 genetic principal components. To control bias from familial relationships in association analysis, we used a relationship-based pruning strategy in plink to exclude 1 member of each pair of samples if the genomic relatedness was greater than 0.2. 32 We used the basic packages and survival package in analyses in R (version 3.4.1; http://www.r-project.org). We used 2-tailed P values and an α level of .05. Analysis was completed from September 2017 to July 2018.
Results Table 1 shows the baseline characteristics of the 411 337 UKBB participants included in this study. Of these, 188 725 participants (45.9%) were male. The mean (SD) age of participants was 56.6 (8.0) years, with a mean (SD) IOPcc of 16.1 (3.5) mm Hg and a mean (SD) IOPg of 15.9 (3.6) mm Hg. We observed a trend that the mean level of IOP increased with age.
Among the 411 337 UKBB participants, 7997 individuals with glaucoma (1.9%) were identified. A total of 1111 individuals with POAG were identified by an ICD-9 or ICD-10 diagnosis of primary open-angle glaucoma.
From 411 337 UKBB participants, it was estimated that 1046 carried the p.Gln368Ter AG genotype. The minor allele frequency (MAF) of risk allele A of p.Gln368Ter was 1 of 786 participants (0.13%), and the observed MAFs were roughly the same across different age groups. As expected, given the frequency, no AA homozygotes were observed.
The MYOC p.Gln368Ter penetrance and its association with glaucoma and OHT are summarized in Table 2 . The penetrance of p.Gln368Ter in glaucoma was estimated to be 7.6% (n = 79 of 1046); in POAG, it was 1.6% (n = 16 of 1046); in OHT, 24.3% (n = 52 of 214); and in OHT or glaucoma combined, it was estimated to be 30.8% (n = 66 of 214). The odds ratio of p.Gln368Ter in glaucoma was 4.40 (95% CI, 3.38-5.71); in POAG, it was 6.76 (95% CI, 4.05-11.29); in OHT, it was 3.56 (95% CI, 2.53-4.92); and in OHT and glaucoma combined, it was 4.18 (95% CI, 3.05-5.67). For p.Gln368Ter carriers, their IOPcc was 2.04 (95% CI, 1.44-2.64) mm Hg higher than in individuals of GG genotype.
In the UKBB, the age-associated prevalence of glaucoma, POAG, OHT, and OHT or glaucoma is summarized in Table 3 and the Figure. In p.Gln368Ter carriers older than 65 years, the prevalence of glaucoma was 15.5% (n = 30); in POAG, it was 4.1% (n = 7); in OHT, 40.0% (n = 20); and in OHT and glaucoma combined, 48.0% (n = 24).
We gathered information on age at glaucoma onset for 4915 individuals; the mean (SD) age at diagnosis was 53.5 (10.8) years. The cumulative risk of glaucoma at 50 years was 2.3% (95% CI, 1.3%-3.2%). At 60 years, it was 8.1% (95% CI, 6.0%-10.3%), and at 65 years, it was 15.6% (95% CI, 11.7%-19.3%; eTable 1 in the Supplement).
In the sequencing-based study, 174 participants in the ANZRAG and GIST registries were found to be Sangervalidated MYOC p.Gln368Ter carriers, including 164 with a known age at diagnosis. Among these 164 individuals (77 male and 87 female), 92 (56.1%) had glaucoma, 24 22 (13.4%) were considered to be glaucoma suspects, and 50 (30.5%) were unaffected. The mean (SD) age at glaucoma diagnosis was 53.2 (12.9) years, and their mean (SD) IOP at diagnosis was 32.5 (9.5) mm Hg. The penetrance of p.Gln368Ter with respect to glaucoma was 56.1% (n = 92); for a wider definition, including both patients with glaucoma and patients who were glaucoma suspects, the penetrance was 69.5% (n = 114; Table 4 ). The Figure and eTable 2 in the Supplement present the age-associated prevalence of glaucoma and suspected glaucoma among p.Gln368Ter carriers in the ANZRAG and GIST registry-based studies. The cumulative risk of glaucoma in MYOC p.Gln368Ter carriers at 50 years was 55.9% (95% CI, 44.1%-67.7%); at age 60 years, it was 80.5% (95% CI, 71.9%-89.1%), and at 65 years, it was 87.1% (95% CI, 79.9%-94.2%). The cumulative risk of patients being considered to have glaucoma or be glaucoma suspects was 77.6% (95% CI, 66.9%-88.3%) at age 50 years, 94.4% (95% CI, 89.6%-99.2%) at age 60 years, and 96.0% (95% CI, 92.1%-99.8%) at age 65 years (eTable 3 in the Supplement). Based on imputed p.Gln368Ter status, the odds of p.Gln368Ter among individuals with advanced glaucoma were 12.2 (95% CI, 6.3-25.0), and for those with nonadvanced glaucoma, they were 3.97 (95% CI, 1.6-9.8).
Discussion
To our knowledge, this is the largest study to examine the penetrance and association of the MYOC p.Gln368Ter variant with glaucoma and OHT in a cohort of individuals of European ancestry and compare it with data from 2 large registry-based studies. We found that p.Gln368Ter was robustly associated with glaucoma, POAG, and OHT and that its penetrance increased with age.
The p.Gln368Ter variant was well imputed (with an imputation quality score of 93.8%), and the MAF was 0.13% in the UKBB data. In this study, the MAF was similar to those reported from exome sequencing databases . 20 The lower MAF seen in the TwinsUK cohort suggests that the set of volunteers ascertained was biased toward healthy individuals. In the UKBB study, individuals with POAG or glaucoma were identified by ICD-9 or ICD-10 diagnosis or self-reported questionnaires; the prevalence of POAG was estimated at With approximately 100 000 participants with IOP measurements, our study provided a more robust estimation of p.Gln368Ter penetrance in OHT in population-based studies. However, the number of individuals with POAG was much lower than expected, given the typical prevalence of POAG in Europe (2.51%). 1 Hence, the true penetrance of p.Gln368Ter in POAG is likely to be larger than estimated in the UKBB samples in this analysis. This again may reflect the bias of a volunteer-based study design. 37 We also proposed a method to calculate the penetrance of p.Gln368Ter based on its odds ratio, MAF, and disease prevalence (eMethods in the Supplement). According to the proposed method, if the prevalence of glaucoma was 2.93% and that of POAG is 2.51% in populations older than 40 years, then using the odds ratios and MAF of p.Gln368Ter from the UKBB, the estimated overall penetrance of p.Gln368Ter for glaucoma was derived to be 10.7% and that of POAG was derived to be 15.1%.
The penetrance of p.Gln368Ter with respect to OHT and glaucoma combined is a more comprehensive indicator. This study showed that in p.Gln368Ter carriers, the cumulative risk of OHT or glaucoma was 38.69% at age 65 years in the population-based study and 95.96% in glaucoma-based registries; p.Gln368Ter genotyping has great potential for early identification of individuals at risk for developing these eye diseases 19, 31, 38 The penetrance of p.Gln368Ter with respect to glaucoma in the UKBB data was lower than in the family studies. There are several potential reasons for this. On the one hand, estimates from family studies may have been inflated by ascertainment bias. On the other hand, the penetrance in general population-based studies may be underestimated because of undersampling of affected individuals. Furthermore, it remains possible that aggregated genetic and environmental risk factors in family studies may have led to increased penetrance in p.Gln368Ter carriers. Recruitment based on families with multiple affected individuals is likely to lead to an increase in the number of common variants of individually small effect (polygenes) in a family, potentially increasing the penetrance of variants such as p.Gln368Ter. This supports the use of cascade testing for close relatives who share the same genetic background.
Limitations
This study has some limitations. The genotypes of p.Gln368Ter in the UKBB study are based on best-guess imputed genotypes. Reassuringly, our previous study presented evidence that the p.Gln368Ter variant could be imputed with high accuracy. 17 Thus, the imputed genotype is unlikely to make a meaningful difference in our results.
Another limitation of the UKBB study is that some individuals with glaucoma were defined by self-reported questionnaires, which could lead to recall bias. However, our study is one of the largest studies to investigate the penetrance and risk effect of p.Gln368Ter in OHT, which could serve as a proxy for glaucoma or POAG. 20 Furthermore, individuals with glaucoma who also have other eye disorders may be less likely to participate the UKBB project, compared with healthy individuals, 37 which could lead to a lower estimated penetrance of p.Gln368Ter in glaucoma. Moreover, in the ANZRAG and GIST registries, the controls were genotyped on different platforms. As a sensitivity analysis, we substituted the Australian control participants for controls from the UKBB data; our results were essentially unchanged. Finally, some individuals with high IOP present in the UKBB cohort may be taking medications or have undergone ophthalmic surgery to reduce their IOP levels. In our sensitivity analysis to adjust for the change in IOP postmedication, when we added 25% to the measured IOP levels for individuals taking IOP-lowering medications, 39,40 the resultant odds ratios and penetrance with respect to OHT increased only slightly.
Conclusions
Our study suggests that the MYOC p.Gln368Ter variant has a high penetrance in OHT and glaucoma. Genetic testing for p.Gln368Ter could help identify individuals who at greater risk of developing glaucoma and direct them to early screening and appropriate management. Twenty-one years later, mutations in MYOC remain the most common molecularly defined cause of glaucoma and are responsible for 3% to 4% of adult-onset POAG cases.
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Glaucoma associated with MYOC is transmitted with autosomal dominant inheritance 3 ; offspring from parents with glaucoma caused by a MYOC mutation have a 50% chance of inheriting the mutation and increased risk for glaucoma. The most common glaucoma-associated MYOC mutation is a nonsense mutation, Gln368Stop, that produces truncated MYOC protein that is missing its last quarter. 2 This mutation has been detected in 1.6% of patients with POAG in large case-control studies and is responsible for more glaucoma than any other known mutation. 2 In their article in JAMA Ophthalmology,
Han et al 4 evaluated very large study populations to investigate just how high the risk for glaucoma is for those with this MYOC mutation. Not all of those with a Gln368Stop mutation have glaucoma. Some do not have glaucoma at the time of an initial examination but may develop disease later in life, while others will never develop glaucoma despite having the mutation. The proportion of people with a mutation (eg, Gln368Stop) that have an associated disease (eg, POAG and/or ocular hypertension) is referred to as the penetrance of that mutation. Determining the penetrance of a diseaseassociated mutation is of paramount importance for accurate diagnostic and prognostic counseling. Moreover, new potential drug therapies 5 and genome-editing therapies 6 are being developed for MYOC-associated glaucoma and their ultimate usefulness may be influenced by estimates of the penetrance of MYOC mutations. Prior studies have estimated the penetrance of the Gln368Stop mutation. Penetrance was first calculated with studies 7, 8 of large pedigrees of patients with glaucoma caused by the Gln368Stop mutation. These pedigree-based studies 7, 8 have suggested that the Gln368Stop mutation has a high penetrance that is age dependent. Among these families, the proportion of mutation carriers with glaucoma was found to increase to 73% to 100% by the seventh decade of life. While pedigree studies suggested that most Gln368Stop mutation carriers ultimately develop disease, populationbased studies have indicated that this mutation may have a lower penetrance in other patient cohorts. In 2016, Nag et al 
eMethods.
Penetrance of p.Gln368Ter based on OR, prevalence and MAF
Introduction
Here, we proposed a method to estimate the penetrance of p.Gln368Ter with respect to glaucoma and POAG based on its odds ratio (OR), disease prevalence and minor allele frequency (MAF) in population-based studies.
First, as to OR, OR = exposure(Genotype) disease health
Then, Prevalence (P), P = , where N = a+b+c+d
We need Penetrance = . So if we know the ratio between , we can get the penetrance. Actually, as to penetrance, it is not related to N ( only related to the ratio of ). We only need P, OR and MAF to get penetrance.
Function to calculate penetrance

Given
To solve the above equations First, we define x = , based on the above equations, we could get:
* (1-P) + x * (1-P-2* MAF + 2 * MAF * OR -P * OR) -P * OR = 0 © 2018 American Medical Association. All rights reserved.
We can use the function uniroot.all in R package rootSolve to solve the equation. The following is the R function to calculate the penetrance based on OR, prevalence and MAF. It also shows that it can calculate the exact penetrance with respect to galucoma, POAG and ocular hypertension (OHT) as we reported in the paper. Besides, since the disease (glaucoma or POAG) is rare (< 3%), the MAF of p.Gln368Ter is about 0.13%, we could get a simple formula to calculate penetrance. 
library(rootSolve)
f_penetrance<
Given
Usage of penetrance function in UK Biobank
Since the prevalence of glaucoma and POAG in UK Biobank is much low than previous reported result. If we we use the OR from the UK Biobank and the prevalence of glaucoma and POAG in
European from previous study, we can calculate the theory penetrance:
# prevalence of glaucoma and POAG from previous study P_glaucoma<-2.93/100
P_poag<-2.51/100
# OR of glaucoma and POAG in UK Biobank
OR_glaucoma<-4
OR_poag<-7
# we can calculate the expected penetrance with respect to glaucoma and POAG f_penetrance(OR=OR_glaucoma,P=P_glaucoma,MAF = 0.13/100) Since all studies can be biased, we cannot get the exact OR, MAF or prevalence. Here, we use a simulation data to investigate the relation between the penetrance of p.Gln368Ter and OR, MAF and prevalence.
# the range of OR
OR=c(seq(2,10,2),7);OR 
